Worth reading
79Important
Scored from 2 of 5 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
300
USD millionWording
Conditional
How definitive the wording is.This transaction
The acquisitionCounterparty (target company)Cullgen Inc.
Disclosing companyGNI Group Ltd.
Execution Date / Effective Date7 May 2026 (acquisition completed)
Target company
Unlisted clinical-stage biopharmaceutical company
Consideration and expenses
Acquisition priceApproximately US$300 million
Type of ConsiderationShares (entirely through a share exchange)
Procedures and assumptions
Management structure after acquisitionDr. Ying Luo, Cullgen's former CEO, became Gyre's President and Chief Executive Officer (CEO), and Ping Zhang serves as Chair of Gyre. The combined company will remain listed on Nasdaq under the ticker symbol "GYRE". Details regarding employee treatment: Not disclosed
| Item | Details |
|---|---|
| Transaction name | The acquisition |
| Counterparty name | Cullgen Inc. |
| Name of the Subject Company | Cullgen Inc. |
| Business Description of the Subject Company | Unlisted clinical-stage biopharmaceutical company |
| Acquisition price | Approximately US$300 million |
| Type of Consideration | Shares (entirely through a share exchange) |
| Execution Date / Effective Date | 7 May 2026 (acquisition completed) |
| Management structure after acquisition | Dr. Ying Luo, Cullgen's former CEO, became Gyre's President and Chief Executive Officer (CEO), and Ping Zhang serves as Chair of Gyre. The combined company will remain listed on Nasdaq under the ticker symbol "GYRE". Details regarding employee treatment: Not disclosed |
Items this document does not state (24)
Location of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceDate of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Gyre explained that, following the acquisition, it aims to achieve global growth as a fully integrated biopharmaceutical company based in the United States and China by combining its commercialized revenue-generating assets, products and development candidates for fibrotic and inflammatory diseases, and Cullgen's drug discovery platform for targeted protein degraders (TPDs) and TPD antibody conjugates (DACs).
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.